ATE536187T1 - Hla-klasse-i- und -klasse-ii-bindende peptide und ihre verwendungen - Google Patents

Hla-klasse-i- und -klasse-ii-bindende peptide und ihre verwendungen

Info

Publication number
ATE536187T1
ATE536187T1 AT07023116T AT07023116T ATE536187T1 AT E536187 T1 ATE536187 T1 AT E536187T1 AT 07023116 T AT07023116 T AT 07023116T AT 07023116 T AT07023116 T AT 07023116T AT E536187 T1 ATE536187 T1 AT E536187T1
Authority
AT
Austria
Prior art keywords
class
binding peptides
peptides
hla
hla class
Prior art date
Application number
AT07023116T
Other languages
English (en)
Inventor
Alessandro Sette
John Sidney
Scott Southwood
Original Assignee
Epimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epimmune Inc filed Critical Epimmune Inc
Application granted granted Critical
Publication of ATE536187T1 publication Critical patent/ATE536187T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT07023116T 2000-10-19 2001-10-18 Hla-klasse-i- und -klasse-ii-bindende peptide und ihre verwendungen ATE536187T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24235000P 2000-10-19 2000-10-19
US28562401P 2001-04-20 2001-04-20

Publications (1)

Publication Number Publication Date
ATE536187T1 true ATE536187T1 (de) 2011-12-15

Family

ID=26935024

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07023116T ATE536187T1 (de) 2000-10-19 2001-10-18 Hla-klasse-i- und -klasse-ii-bindende peptide und ihre verwendungen

Country Status (5)

Country Link
EP (2) EP1455816A4 (de)
AT (1) ATE536187T1 (de)
AU (1) AU2001298049A1 (de)
CA (1) CA2425648A1 (de)
WO (1) WO2003040165A2 (de)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002048175A2 (en) * 2000-12-13 2002-06-20 Argonex Pharmaceuticals Mhc class i associated peptides for prevention and treatment of tuberculosis
WO2003008537A2 (en) * 2001-04-06 2003-01-30 Mannkind Corporation Epitope sequences
US20060222656A1 (en) 2005-04-01 2006-10-05 University Of Maryland, Baltimore MAGE-A3/HPV 16 peptide vaccines for head and neck cancer
US7049413B2 (en) * 2001-05-18 2006-05-23 Ludwig Institute For Cancer Research MAGE-A3 peptides presented by HLA class II molecules
WO2002094994A2 (en) 2001-05-18 2002-11-28 Mayo Foundation For Medical Education And Research Chimeric antigen-specific t cell-activating polypeptides
EP3184539A3 (de) 2001-10-23 2017-09-13 PSMA Development Company L.L.C. Psma antikörper
US20050215472A1 (en) 2001-10-23 2005-09-29 Psma Development Company, Llc PSMA formulations and uses thereof
JP5097400B2 (ja) * 2003-09-03 2012-12-12 デンドリセラピューティクス、インク． 複合ワクチン
IL157772A (en) * 2003-09-04 2016-06-30 Bmr Solutions Ltd Compounds containing oligopeptide derived from turtle larvae and their use to encourage mammalian hemophysis
WO2005037855A2 (en) * 2003-10-17 2005-04-28 Pecos Labs, Inc. T cell epitopes useful in a yersinia pestis vaccine and as diagnostic tools and methods for identifying same
EP1732598A4 (de) * 2003-12-31 2009-08-26 Pharmexa Inc Auslösung von zellulären immunantworten gegen den humanen papillovirus unter verwendung von peptid und nucleinsäure-zusammensetzungen
GB0406054D0 (en) * 2004-03-17 2004-04-21 Univ Nottingham Trent Prostatic acid phosphatase antigens
GB0716992D0 (en) 2007-08-31 2007-10-10 Immune Targeting Systems Its L Influenza antigen delivery vectors and constructs
GB0408164D0 (en) 2004-04-13 2004-05-19 Immune Targeting Systems Ltd Antigen delivery vectors and constructs
JP4761311B2 (ja) * 2004-04-30 2011-08-31 日本電気株式会社 Ｈｌａ結合性ペプチド、それをコードするｄｎａ断片および組み換えベクター
JP4731867B2 (ja) 2004-10-01 2011-07-27 国立大学法人三重大学 Ｃｄ８陽性の細胞傷害性ｔリンパ球の誘導方法
DE102004049223A1 (de) 2004-10-08 2006-04-20 Johannes-Gutenberg-Universität Mainz Zubereitung zum Impfen, Impfverfahren und Verwendung einer Impf-Zubereitung
EP1709971A1 (de) * 2005-04-06 2006-10-11 Ganymed Pharmaceuticals AG Peptidantigene zur Verwendung in Prophylaxe, Behandlung und Diagnose von Poxvirusinfektionen
AU2006259307B2 (en) * 2005-06-17 2012-12-20 Mannkind Corporation Epitope analogues
BRPI0504117A (pt) 2005-09-05 2007-05-22 Fundacao De Amparo A Pesquisa epìtopos, combinação de epìtopos, usos de epìtopos ou sua combinação, composição, usos da composição, vacinas profiláticas anti-hiv-1, vacinas terapêuticas, método para a identificação de epìtopos e métodos para o tratamento ou prevenção
DE602007005354D1 (de) * 2006-01-25 2010-04-29 Viro Pharmaceuticals Gmbh & Co Humaner verstärker der viralen infektion (sevi) und seine anwendung
US20100168034A1 (en) * 2006-02-20 2010-07-01 Ewha University-Industry Collaboration Foundation Peptide having cell membrane penetrating activity
EP1840133A1 (de) * 2006-03-29 2007-10-03 Global Biotech Development Corp. Ltd. Neue immunomodulierende Oligopeptide
US20080107668A1 (en) * 2006-08-30 2008-05-08 Immunotope, Inc. Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
EP2476697B1 (de) 2006-10-17 2015-06-17 Oncotherapy Science, Inc. Peptidvakzinen für MPHOSPH1-Polypeptide exprimierenden Krebs
US20090117140A1 (en) * 2007-09-26 2009-05-07 Mayumi Nakagawa Human papilloma virus dominant CD4 T cell epitopes and uses thereof
ES2627306T3 (es) * 2007-11-20 2017-07-27 Vianex S.A. Análogos de péptido y conjugados de los mismos
WO2009067584A1 (en) * 2007-11-20 2009-05-28 Duke University Methods and compositions for modulating drug-polymer architecture, pharmacokinetics and biodistribution
DK2234635T3 (en) * 2007-12-19 2017-05-01 Rhovac Aps RhoC-based immunotherapy
US20100166782A1 (en) * 2008-07-25 2010-07-01 Martha Karen Newell Clip inhibitors and methods of modulating immune function
US8975086B2 (en) 2008-08-28 2015-03-10 Oncotherapy Science, Inc. Method for treating or preventing bladder cancer using the DEPDC1 polypeptide
ES2574988T3 (es) 2008-10-06 2016-06-23 Yissum Research Development Company Of The Herbrew University Of Jerusalem Ltd. Péptidos derivados de estimulantes de la VIH-1 integrasa que interfieren con la proteína Rev-integrasa
JP5792630B2 (ja) 2009-01-28 2015-10-14 エピミューン，インコーポレイティド Ｐａｎ−ｄｒ結合ポリペプチドおよびその使用
JP5317336B2 (ja) * 2009-02-23 2013-10-16 国立大学法人東北大学 質量分析装置を用いたタンパク質定量のための評価用ペプチド、人工標準タンパク質、及びタンパク質の定量方法
CA2756238A1 (en) * 2009-04-02 2010-10-07 Vaxon Biotech Identification, optimization and use of cryptic hla-a24 epitopes for immunotherapy
US8431530B2 (en) * 2009-06-12 2013-04-30 Morehouse School Of Medicine Compositions and methods for treating aids or cancer by inhibiting the secretion of microparticles
US9023802B2 (en) * 2009-12-14 2015-05-05 Immatics Biotechnologies Gmbh HLA-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
CN103732743B (zh) 2011-08-12 2017-03-15 肿瘤疗法科学股份有限公司 Mphosph1肽及包含它们的疫苗
GB201300683D0 (en) * 2013-01-15 2013-02-27 Apitope Int Nv Peptide
US10392611B2 (en) 2013-05-30 2019-08-27 Duke University Polymer conjugates having reduced antigenicity and methods of using the same
US10364451B2 (en) 2013-05-30 2019-07-30 Duke University Polymer conjugates having reduced antigenicity and methods of using the same
JP6692294B2 (ja) 2013-07-31 2020-05-13 バイオベンチャーズ・リミテッド・ライアビリティ・カンパニーＢｉｏＶｅｎｔｕｒｅｓ， ＬＬＣ 腫瘍関連糖鎖抗原を標的として癌を治療及び予防するための組成物及び方法
EP3140317B1 (de) 2014-05-09 2020-04-15 University Of Southampton Peptidinduzierte nk-zellen-aktivierung
US10385115B2 (en) 2015-03-26 2019-08-20 Duke University Fibronectin type III domain-based fusion proteins
GB201505305D0 (en) 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
DK3273986T3 (da) 2015-03-27 2024-02-12 Immatics Biotechnologies Gmbh Hidtil ukendte peptider og kombination af peptider til anvendelse ved immunterapi mod forskellige tumorer
EP3319630A1 (de) 2015-07-09 2018-05-16 Intervacc AB Impfstoff gegen s. suis-infektion
JP6882782B2 (ja) 2015-08-04 2021-06-02 デューク ユニバーシティ 遺伝子コードされた本質的に無秩序な送達用ステルスポリマーおよびその使用方法
GB201513921D0 (en) 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
EP3336186A4 (de) 2015-08-12 2019-03-06 OncoTherapy Science, Inc. Depdc1-abgeleitetes peptid und impfstoff damit
EP3360885A4 (de) 2015-10-08 2019-04-24 Oncotherapy Science, Inc. Von mphosph1 abgeleitetes peptid und impfstoff damit
GB201520570D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
US11752213B2 (en) 2015-12-21 2023-09-12 Duke University Surfaces having reduced non-specific binding and antigenicity
US11467156B2 (en) 2016-06-01 2022-10-11 Duke University Nonfouling biosensors
RU2019110848A (ru) 2016-09-14 2020-10-15 Дьюк Юниверсити Наночастицы на основе триблочных полипептидов для доставки гидрофильных лекарственных средств
WO2018057847A1 (en) 2016-09-23 2018-03-29 Duke University Unstructured non-repetitive polypeptides having lcst behavior
WO2018085751A1 (en) * 2016-11-07 2018-05-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Development of agonist epitopes of the human papillomavirus
WO2018132732A1 (en) 2017-01-12 2018-07-19 Duke University Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly
US20230241207A1 (en) * 2017-04-03 2023-08-03 Neon Therapeutics, Inc. Protein antigens and uses thereof
WO2018213320A1 (en) 2017-05-15 2018-11-22 Duke University Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents
WO2019006374A1 (en) 2017-06-30 2019-01-03 Duke University ORDER AND DISORDER AS A DESIGN PRINCIPLE FOR STIMULI-SENSITIVE BIOPOLYMER NETWORKS
TW202019955A (zh) * 2018-07-31 2020-06-01 德商英麥提克生物技術股份有限公司 B*07 限制肽和肽組合的抗癌免疫治療和相關方法
EP3829622A4 (de) 2018-08-02 2022-05-11 Duke University Doppel-agonisten-fusionsproteine
US11512314B2 (en) 2019-07-12 2022-11-29 Duke University Amphiphilic polynucleotides
JP2022542119A (ja) * 2019-07-24 2022-09-29 アジェナス インコーポレイテッド 抗原性ポリペプチドおよびその使用方法
NL2030990B1 (en) * 2022-02-17 2023-09-01 Academisch Ziekenhuis Leiden T cell receptors directed against jchain and uses thereof
CN117285597B (zh) * 2023-11-27 2024-01-26 中国科学院烟台海岸带研究所 一种具有降尿酸功能的五肽kk5及其应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4844893A (en) 1986-10-07 1989-07-04 Scripps Clinic And Research Foundation EX vivo effector cell activation for target cell killing
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
ATE342730T1 (de) 1992-08-07 2006-11-15 Pharmexa Inc Hla bindepeptide und ihre verwendungen
AU6359494A (en) 1993-03-05 1994-09-26 Epimmune, Inc. Hla-a2.1 binding peptides and their uses
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
DK0735893T3 (da) 1993-09-14 2009-03-09 Pharmexa Inc PAN DR-bindende peptider til styrkelse af immunsvaret
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5922687A (en) 1995-05-04 1999-07-13 Board Of Trustees Of The Leland Stanford Junior University Intracellular delivery of nucleic acids using pressure
US6019974A (en) 1996-01-26 2000-02-01 Emory University SPE-4 peptides
EP0960204A4 (de) 1996-07-26 2002-01-23 Sloan Kettering Inst Cancer Methoden und reagenzien zur genetischen immunisierung
US6128946A (en) 1997-06-26 2000-10-10 Crane Nuclear, Inc. Method and apparatus for on-line detection of leaky emergency shut down or other valves
FR2771640B1 (fr) * 1997-12-03 2000-02-11 Inst Nat Sante Rech Med Micelles mixtes de lipopeptides pour l'induction d'une reponse immunitaire et leurs utilisations a des fins therapeutiques
AU6226100A (en) 1999-07-19 2001-04-24 Epimmune, Inc. Inducing cellular immune responses to hepatitis c virus using peptide and nucleic acid compositions
US7026443B1 (en) 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions

Also Published As

Publication number Publication date
EP1455816A2 (de) 2004-09-15
EP1911461B1 (de) 2011-12-07
AU2001298049A1 (en) 2003-05-19
WO2003040165A3 (en) 2004-06-24
EP1455816A4 (de) 2007-03-28
WO2003040165A2 (en) 2003-05-15
EP1911461A2 (de) 2008-04-16
EP1911461A3 (de) 2008-07-16
AU2001298049A8 (en) 2005-11-03
CA2425648A1 (en) 2002-04-19

Similar Documents

Publication Publication Date Title
ATE536187T1 (de) Hla-klasse-i- und -klasse-ii-bindende peptide und ihre verwendungen
ATE512666T1 (de) Hla-bindende peptide und ihre verwendungen
DE69334076D1 (de) Hla bindepeptide und ihre verwendungen
BR9406652A (pt) Composição
DE69733352D1 (de) Hla-a2.1 bindende peptide und deren verwendung
DK0941478T3 (da) Assaymetode for peptidspecifikke T-celler
DE60142689D1 (de) Verwendung prokariotischer pest-ähnlicher peptide zur verstärkung der immunogenität von antigenen
ATE493186T1 (de) Zelltrennungszusammensetzungen und -verfahren
DK1553832T3 (da) Præparater og fremgangsmåder til celleseparering
BR0017136A (pt) Peptìdeos de ligação ao hla e seus usos.
ATE429247T1 (de) Hla-bindende peptide und ihre verwendungen
DK1530637T3 (da) Carlsberg-subtilisin-proteiner med nedsat immunogenitet
ATE551069T1 (de) Mucin-fusionspolypeptid-vakzine, zusammensetzungen und ihre verwendung
DE60045776D1 (de) Hla-bindungspeptide und ihre anwendungszwecke
WO2004007528A3 (en) Novel compositions and methods for the generation of mhc class ii compounds by peptide exchange
WO2003091383A3 (fr) Epitopes t de l'antigene epha2.
ATE399176T1 (de) Nonapeptidische ny-eso-1 derivate und deren verwendung
WO2004011483A3 (en) Isolated, ssx-2 and ssx-2 related peptides useful as hla binders and ctl epitopes, and uses thereof
EP1605039A4 (de) Dendritische zelle mit alpha-glycosylceramid-derivat und antigen zur verwendung bei der unterdrückung von immunreaktionen
IL165674A0 (en) Membrane-anchored B2 microglobulin covalently linked to MHC class I peptide epitopes